Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Gross Margin: 2022-2025

Historic Gross Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to 91.25%.

  • Arcutis Biotherapeutics' Gross Margin rose 354.00% to 91.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 89.96%, marking a year-over-year increase of 39.00%. This contributed to the annual value of 90.27% for FY2024, which is 137.00% down from last year.
  • Arcutis Biotherapeutics' Gross Margin amounted to 91.25% in Q3 2025, which was up 0.48% from 90.81% recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Gross Margin peaked at 100.00% during Q1 2022, and registered a low of 62.90% during Q3 2022.
  • For the 3-year period, Arcutis Biotherapeutics' Gross Margin averaged around 87.75%, with its median value being 88.77% (2024).
  • Examining YoY changes over the last 5 years, Arcutis Biotherapeutics' Gross Margin showed a top increase of 3,316bps in 2023 and a maximum decrease of 2,816bps in 2023.
  • Quarterly analysis of 4 years shows Arcutis Biotherapeutics' Gross Margin stood at 83.62% in 2022, then dropped by 23bps to 83.39% in 2023, then surged by 693bps to 90.32% in 2024, then soared by 354bps to 91.25% in 2025.
  • Its Gross Margin was 91.25% in Q3 2025, compared to 90.81% in Q2 2025 and 86.59% in Q1 2025.